Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...

Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...

US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...

Merck was testing the injectable version of the world's biggest selling drug in a late stage trial of patients with a type of ...

Recent health news highlights include WHO's emergency listing of a mpox vaccine, Pfizer's legal setback in recouping ...

Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...

Merck reported good news Tuesday on a more convenient version of its cancer drug Keytruda, a reassuring sign following ...

Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...

Retailers post earnings beats, Bitcoin price hits record, Microsoft conference shows AI progress has slowed, and other news ...